TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide production

Cardiovascular Research

Volumn 100, Issue 1, 2013, Pages 28-35

  Cauwels, Anje ^a,b   Vandendriessche, Benjamin ^a,b   Bultinck, Jennyfer ^a,b   Descamps, Benedicte ^b   Rogge, Elke ^a,b   Van Nieuwenhuysen, Tom ^a,b   Sips, Magdalena ^a,b   Vanhove, Christian ^b   Brouckaert, Peter ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Hypotension; LPS; NOS; Shock; TLR2

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIUM CELL; FEMALE; HYPOTENSION; HYPOTHERMIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MORBIDITY; MOUSE; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHOCK; TISSUE PERFUSION;

HYPOTENSION; LPS; NOS; SHOCK; TLR2;

ANIMALS; CYTOKINES; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MORBIDITY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTOR 2;

EID: 84887897064     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt168     Document Type: Article

References (31)

1. Angus DC, Linde-Zwirble WT, Lidicker J., Clermont G, Carcillo J, Pinsky MR. Epidemi-ologyofsevere sepsisinthe United States: analysisofincidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 2001; 91: 179-213.
3. Cauwels A. Nitric oxide in shock. Kidney Int 2007; 72: 557-565.
4. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57.
5. Pedoto A, Tassiopoulos AK, Oler A, McGraw D.J., Hoffmann SP, Camporesi EM et al. Treatment of septic shock in rats with nitric oxide synthase inhibitors and inhaled nitric oxide. Crit Care Med 1998; 26: 2021-2028.
6. Lopez A, Lorente JA, Steingrub J, Bakker J., McLuckie A, Willatts S et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.
7. Dellinger P, Parrillo J. Mediator modulation therapy of severe sepsis and septic shock: does it work? Crit Care Med 2004; 32: 282-286.
8. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990; 49: 186-196.
9. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650.
10. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
11. Kawai T, Adachi O, Ogawa T., Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-122.
12. Hoebe K, Du X, Georgel P., Janssen E, Tabeta K, Kim SO et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424: 743-748.
13. Shesely EG, Maeda N, Kim H.S., Desai KM, Krege JH, Laubach VE et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93: 13176-13181.
14. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide syn-thase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995; 92: 10688-10692.
15. Hirschfeld M, Ma Y, Weis J.H., Vogel SN, Weis JJ. Cutting edge: repurification of lipopoly-saccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165: 618-622.
16. Cauwels A, Janssen B, Waeytens A., Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003; 4: 387-393.
17. Bultinck J, Brouckaert P, Cauwels A. The in vivo contribution of hematopoietic cells to systemic TNF and IL-6 production during endotoxemia. Cytokine 2006; 36: 160-166.
18. Cauwels A, Rogge E, Janssen B., Brouckaert P. Reactiveoxygen species and small conductance calcium-dependent potassium channels are key mediatorsofinflammation-induced hypotension and shock. J Mol Med 2010; 88: 921-930.
19. Bultinck J, Sips P, Vakaet L., Brouckaert P, Cauwels A. Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. Faseb J 2006; 20: 2363-2365.
20. Ignarro LJ, Buga GM, Wood K.S., Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
21. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
22. Cauwels A, Brouckaert P. Nitrite regulation of shock. Cardiovasc Res 2011; 89: 553-559.
23. Cauwels A, Bultinck J, Brouckaert P. Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress. Cell Mol Life Sci 2005; 62: 1632-1640.
24. Mao K, Chen S, Chen M., Ma Y, Wang Y, Huang B et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res 2013; 23: 201-212.
25. Cauwels A, Buys ES, Thoonen R, Geary L., Delanghe J, Shiva S et al. Nitrite protectsagainst morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guany-late cyclase-dependent manner. J Exp Med 2009; 206: 2915-2924.
26. Capettini LS, Cortes SF, Lemos VS. Relative contribution of eNOS and nNOS to endothelium-dependent vasodilation in the mouse aorta. Eur J Pharmacol 2010; 643: 260-266.
27. Munzel T, Gori T, Bruno R.M., Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010; 31: 2741-2748.
28. Harrison DG, Chen W, Dikalov S., Li L. Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications. Adv Pharmacol 2010; 60: 107-132.
29. Seok J, Warren HS, Cuenca A.G., Mindrinos MN, Baker HV, Xu W et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.
30. Copeland S, Warren HS, Lowry S.F., Calvano SE, Remick D. Acuteinflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12: 60-67.
31. Juskewitch JE, Knudsen BE, Platt J.L., Nath KA, Knutson KL, Brunn GJ et al. LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol 2012; 180: 32-40.